Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings
Author:
Schröder MartinORCID, Renatus MartinORCID, Liang Xiaoyou, Meili Fabian, Zoller Thomas, Ferrand Sandrine, Gauter Francois, Li Xiaoyan, Sigoillot Fred, Gleim Scott, Stachyra Marie-Therese, Thomas Jason, Begue Damien, Lefeuvre Peggy, Andraos-Rey Rita, Chung BoYee, Ma Renate, Carbonneau Seth, Pinch Benika, Hofmann Andreas, Schirle Markus, Schmiedberg Niko, Imbach Patricia, Gorses Delphine, Calkins Keith, Bauer-Probst Bea, Maschlej Magdalena, Niederst Matt, Maher Rob, Henault Martin, Alford John, Ahrne Erik, Hollingworth Greg, Thomä Nicolas H.ORCID, Vulpetti AnnaORCID, Radimerski Thomas, Holzer Philipp, Thoma Claudio R.ORCID
Abstract
ABSTRACTTargeted protein degradation (TPD) of neo-substrates with proteolysis targeting chimeras (PROTACs) or molecular glues has emerged as a key modality in exploring new biology as well as designing new drug candidates where catalytic inhibition is neither efficacious nor an option. TPD is mediated through harnessing E3 ligases and redirecting them to ubiquitinatede novotarget proteins for subsequent proteasomal degradation. Until recently, E3 ligase chemical matter available for mediating TPD has been limited to a relatively low number of ligases, considering that over 600 E3 ligases are encoded by the human genome. In addition, the most utilized ligase for TPD approaches, CRBN, has been observed to be downregulated in settings of acquired resistance to immunomodulatory inhibitory drugs (IMiDs). IMiDs are molecular glues that target IKZF transcription factors to CRBN for degradation. Resistance is potentially accelerated by non-essentiality of CRBN for cell viability. Here we investigated if the essential E3 ligase receptor DCAF1 can be harnessed for TPD utilizing a potent, non-covalent DCAF1 binder. We show that this binder, selective for the CRL4DCAF1E3 ligase complex, can be functionalized into an efficient DCAF1-BRD9 PROTAC. Chemical and genetic rescue experiments confirm specific degradation via the CRL4DCAF1E3 ligase. We further highlight the versatility of DCAF1 for TPD by developing a DCAF1-dasatininb PROTAC targeting multiple cytosolic and membrane bound tyrosine kinases. We expand these findings towards Bruton’s tyrosine kinase (BTK) selective PROTACs and through extensive optimization and characterization efforts share key observations that led to a potent and selective DCAF1-BTK PROTAC (DBt-10). Finally, with this PROTAC DBt-10, we show rescue of BTK degradation in a BTK-dependent, CRBN-degradation-resistant cell line and provide a rationale for E3 ligase swap to overcome CRBN mediated resistance.
Publisher
Cold Spring Harbor Laboratory
Reference100 articles.
1. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies;J Hematol Oncol,2022 2. PROTAC targeted protein degraders: the past is prologue;Nat Rev Drug Discov,2022 3. Bonazzi, S. , d’Hennezel, E. , Beckwith, R. E. J. , Xu, L. , Fazal, A. , Magracheva, A. , Ramesh, R. , Cernijenko, A. , Antonakos, B. , Bhang, H. C. , Caro, R. G. , Cobb, J. S. , Ornelas, E. , Ma, X. , Wartchow, C. A. , Clifton, M. C. , Forseth, R. R. , Fortnam, B. H. , Lu, H. , Csibi, A. , Tullai, J. , Carbonneau, S. , Thomsen, N. M. , Larrow, J. , Chie-Leon, B. , Hainzl, D. , Gu, Y. , Lu, D. , Meyer, M. J. , Alexander, D. , Kinyamu-Akunda, J. , Sabatos-Peyton, C. A. , Dales, N. A. , Zécri, F. J. , Jain, R. K. , Shulok, J. , Wang, Y. K. , Briner, K. , Porter, J. A. , Tallarico, J. A. , Engelman, J. A. , Dranoff, G. , Bradner, J. E. , Visser, M. , & Solomon, J. M. (2023). Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chem Biol. https://doi.org/10.1016/j.chembiol.2023.02.005 4. Catalytic in vivo protein knockdown by small-molecule PROTACs 5. Brien, G. L. , Remillard, D. , Shi, J. , Hemming, M. L. , Chabon, J. , Wynne, K. , Dillon, E. T. , Cagney, G. , Van Mierlo, G. , Baltissen, M. P. , Vermeulen, M. , Qi, J. , Fröhling, S. , Gray, N. S. , Bradner, J. E. , Vakoc, C. R. , & Armstrong, S. A. (2018). Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife, 7. https://doi.org/10.7554/eLife.41305
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|